Research: Lennox Gastaut Syndrome

Neuroscience Research | October 24, 2018 | cookchildrens

Lennox Gastaut syndrome (LGS) is a devastating epileptic encephalopathy of childhood. It presents with frequent seizures of multiple types (tonic, atonic, tonic-clonic, absence, myoclonic), cognitive delays and generalized slow spike wave on EEG studies. The seizures are notoriously difficult to control and patients often fail multiple medications, dietary therapy and palliative surgeries. Recognizing the need to find better treatments for this devastating condition, Cook Children's continues to participate in new research using drugs such as low-dose fenfluramine for treatment of seizures associated with LGS.

Cook Children's was the only site in Texas to participate in an earlier study of fenfluramine for Dravet syndrome. Initial data from these earlier studies have demonstrated remarkable reduction in seizure frequency with patients on 0.8 mg/kg/d of fenfluramine experiencing a median 72.4% reduction in convulsive seizures, versus only 17.4% in the placebo group (p<0.001). Nearly half (45%) of treated patients had >75% reduction of seizures, versus only 2.5% in the placebo group (p<0.001). Similarly, mean number of seizure free-days was longer in the treatment group (20.5 days), versus the placebo.

Fenfluramine was formerly a component of the diet drug Fen-Phen and was associated with cardiac valvulopathy prompting withdrawal from the market. Thus far, no significant cardiac valvulopathy or pulmonary hypertension has been noted in trials for epilepsy, possibly due to the lower dosing used in these trials.

Cook Children's Neurosciences team strives to offer new and innovative medication treatments to our patients through clinical trials and research. A number of studies are currently open and enrolling for diagnoses such as epilepsy, dystonia and muscular dystrophy at Cook Children's.

Active Research Studies

Contributing author

Headshot of M. Scott Perry

M. Scott Perry, MD


Card Link

Cook Children's Neurosciences team

Great outcomes begin with great input. Having a medical system where every department, doctor, and care team member works together means that your child can have quick access to testing, diagnosis and treatment, and that means better outcomes now and in the future.

Contact the Jane and John Justin Neuroscience Center at Cook Children's to refer a patient or ask questions: 682-885-2500.

You Might Also Like



Jane and John Justin Neurosciences Center Welcomes Four New Faculty Members

The Jane and John Justin Neurosciences Center is growing to meet the needs of our region. According to the U.S. Census Bureau, Dallas (#3) and Fort Worth (#4) are among a total of five Texas cities listed in the 15 fastest growing large cities and both are listed within the top 15 most populous cities in the country. 

Photo of Lindsey Carnes, Ph.D., neuropsychology faculty member


Cook Children’s Neurosciences welcomes new Neuropsychology faculty member

The Jane and John Justin Neurosciences Center at Cook Children’s continues to grow our faculty to meet the needs of our patients. In January 2022, we welcomed Lindsey Carnes, Ph.D. as our fourth neuropsychologist.



Texas Pediatric Neuroscience Network Conference March 6-8, 2020

The second annual Texas Pediatric Neuroscience Network Conference will be held March 6-8 at the Driskill Hotel in Austin, Texas.